:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Tamer Hassan, Mohsen Elalfy, Mervat A. M. Youssef, Omar Elalfy, Elzahraa Elmasry, Gehan Lotfy Khalifa, Ahmad Darwish, Eslam E. Elhawary
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Haemophilia
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/hae.70310
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis
by: Branislav V. Bajkin, et al.
Published: (2026)

Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
by: Nuchanun Kessakorn, et al.
Published: (2024)

Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis
by: Han Bao, et al.
Published: (2026)

Reduced‐Dose versus Standard‐Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study
by: Huiling Yan, et al.
Published: (2025)

Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia
by: Kyle Davis, et al.
Published: (2026)

Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State
by: Yuki Kawasaki, et al.
Published: (2025)

Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study
by: Ilenia Lorenza Calcaterra, et al.
Published: (2026)

HEAD‐US Score and Cartilage Biomarkers in Patients With Severe Haemophilia A Who Receive Low‐Dose Factor VIII Prophylaxis
by: Arpanan Pramualratthakarn, et al.
Published: (2026)

TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
by: Kagehiro Amano, et al.
Published: (2025)

Managing Acute Coronary Syndrome and Surgical Revascularization in a Patient With Severe Haemophilia A on Emicizumab: Lessons Learned From a Clinical Case
by: Paige Muir, et al.
Published: (2026)

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
by: Midori Shima, et al.
Published: (2025)

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis
by: Konstantina Bolou, et al.
Published: (2025)

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment
by: Yesim Dargaud, et al.
Published: (2025)

Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia
by: Nathália Martins Beserra, et al.
Published: (2026)

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post‐Marketing Study
by: Pål André Holme, et al.
Published: (2025)

Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
by: Luigi Piero Solimeno, et al.
Published: (2025)

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
by: Daniel Kraemmer, et al.
Published: (2025)

Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry
by: Aikaterini Michalopoulou, et al.
Published: (2025)

Impact of Family History of Haemophilia on Diagnosis, Management and Outcomes in Severe Haemophilia
by: Ana Mendoza, et al.
Published: (2025)

Muscle Strength in Children and Adolescents With Haemophilia on Prophylaxis: An Age‐Adjusted Dynamometric Study
by: Dimitrios Syrengelas, et al.
Published: (2026)

Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A
by: Johnny Mahlangu, et al.
Published: (2025)

Preclinical Atherosclerosis in Adolescents With Severe Haemophilia
by: Christian Saleh, et al.
Published: (2026)

Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort
by: Rubén Berrueco, et al.
Published: (2026)

Haemophilia Joint Health Score Ranges Across the Lifespan: Variation by Haemophilia Type and Severity
by: Beth Boulden Warren, et al.
Published: (2026)

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study
by: Midori Shima, et al.
Published: (2026)

A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A
by: Dagmar M. Hajducek, et al.
Published: (2025)

Efficacy and Safety of rVIII‐SingleChain in Surgical Prophylaxis
by: Faraizah Abdul Karim, et al.
Published: (2025)

Emicizumab and asparaginase, A first experience to share
by: Laurie Goubeau, et al.
Published: (2024)

Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments
by: Ting‐Wei Lyu, et al.
Published: (2026)

Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
by: Kathelijn Fischer, et al.
Published: (2025)

Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia
by: Arun Keepanasseril, et al.
Published: (2025)

Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A
by: Kirollos Kamel, et al.
Published: (2025)

Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
by: Priyanka Raheja, et al.
Published: (2026)

Carotid Intima‐Media Thickness as a Marker of Subclinical Atherosclerosis in Adolescents With Severe Haemophilia
by: Alyson Trillo, et al.
Published: (2025)

Genetic Analysis and Reproductive Interventions for Two Rare Families Affected by Severe Haemophilia A
by: Shimin Yuan, et al.
Published: (2024)

Quality of Life and Treatment Satisfaction in People With Haemophilia on Fitusiran Prophylaxis: Evidence From a Subset of ATLAS‐OLE Trial Participants Mainly From India
by: Alok Srivastava, et al.
Published: (2025)

Emicizumab plasma levels after accelerated saturation in acquired haemophilia A
by: Tristan Kloeter, et al.
Published: (2024)

UK Experience of Children With Inhibitors in Severe Haemophilia B: A Report by the UKHCDO Paediatric Working Party
by: Mary Mathias, et al.
Published: (2026)

Circulating and Synovial Fluid Levels of YKL‐40 Protein in Patients With Severe Haemophilia A: Preliminary Observations
by: Aikaterini Michalopoulou, et al.
Published: (2026)

Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata
by: Nita Radhakrishnan, et al.
Published: (2026)